Treace Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2026 ACFAS Annual Scientific Conference

PONTE VEDRA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™, MTA3D™, and SpeedMTP® clinical studies at the American College of Foot and Ankle Surgeons (“ACFAS”) Annual Scientific Conference in Las Vegas, Nevada from February 24-26, 2026.

GlobeNewsWire • 14 hours ago

First Eagle Small Cap Opportunity Fund Q4 2025 Portfolio Review

First Eagle Small Cap Opportunity Fund A Shares (without sales charge*) posted a return of 1.71% in fourth quarter 2025. Small Cap Opportunity Fund A Shares (without sales charge*) posted a return of 1.71% in fourth quarter 2025.

Seeking Alpha • Feb 19, 2026

Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026

PONTE VEDRA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the fourth quarter and full year of 2025 before the open of trading on Friday, February 27, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET.

GlobeNewsWire • Feb 12, 2026

Treace Medical Concepts, Inc. (TMCI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Treace Medical Concepts, Inc. (TMCI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 14, 2026

Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue

PONTE VEDRA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced its preliminary, unaudited fourth quarter and full-year 2025 revenue results.

GlobeNewsWire • Jan 13, 2026

Treace Announces First Surgical Case Utilizing Lapiplasty® Lightning™ Technology

PONTE VEDRA, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced the successful completion of the first case utilizing its Lapiplasty® Lightning™ technology.

GlobeNewsWire • Jan 8, 2026

Treace Medical Secures Up to $175 Million in Debt Financing

New 5-Year Agreement Provides Continued Financial Strength & Flexibility New 5-Year Agreement Provides Continued Financial Strength & Flexibility

GlobeNewsWire • Dec 18, 2025

Treace Medical Concepts, Inc. (TMCI) Q3 2025 Earnings Call Transcript

Treace Medical Concepts, Inc. ( TMCI ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Trip Taylor John Treace - Founder, Chairman & CEO Mark Hair - Chief Financial Officer Conference Call Participants Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division Marie Thibault - BTIG, LLC, Research Division Jayna Renee Francis - UBS Investment Bank, Research Division Presentation Trip Taylor Good afternoon, everyone, and welcome to our third quarter 2025 earnings conference call. Participating from the company today will be John Treace, Chief Executive Officer; and Mark Hair, Chief Financial Officer.

Seeking Alpha • Nov 7, 2025

Treace Announces Participation in Two Upcoming Investor Conferences

PONTE VEDRA, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will participate in the following upcoming investor conferences.

GlobeNewsWire • Nov 7, 2025

Treace Medical Concepts (TMCI) Reports Q3 Loss, Beats Revenue Estimates

Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.25 per share a year ago.

Zacks Investment Research • Nov 6, 2025